8_larynx

Larynx

31

Larynx (ICD‐O‐3 C32.0‐2, C10.1)

The classification applies only to carcinomas. There should be histological confirmation of the disease.

The following are the procedures for assessing T, N, and M categories: T categories Physical examination, laryngoscopy, and imaging N categories Physical examination and imaging M categories Physical examination and imaging

Anatomical Sites and Subsites 1. Supraglottis (C32.1) a) Suprahyoid epiglottis [including tip, lingual (anterior) (C 10.1), and laryngeal surfaces] b) Aryepiglottic fold, laryngeal aspect c) Arytenoid d) Infrahyoid epiglottis e) Ventricular bands (false cords) 2. Glottis (C32.0) a) Vocal cords b) Anterior commissure c) Posterior commissure 3. Subglottis (C32.2)

}

E pilarynx (including marginal zone)

excluding } Supraglottis epilarynx

Regional Lymph Nodes The regional lymph nodes are the cervical nodes.

TNM Clinical Classification T – Primary Tumour TX Primary tumour cannot be assessed T0 No evidence of primary tumour Tis Carcinoma in situ

Head & Neck

Rules for Classification

32

Head and Neck Tumours

Supraglottis T1 Tumour limited to one subsite of supraglottis with normal vocal cord mobility T2 Tumour invades mucosa of more than one adjacent subsite of supraglottis or glottis or region outside the supraglottis (e.g., mucosa of base of tongue, vallecula, medial wall of piriform sinus) without fixation of the larynx T3 Tumour limited to larynx with vocal cord fixation and/or invades any of the following: postcricoid area, pre�epiglottic space, paraglottic space, and/or inner cortex of thyroid cartilage T4a Tumour invades through the thyroid cartilage and/or invades tissues beyond the larynx, e.g., trachea, soft tissues of neck including deep/extrinsic muscle of tongue (genioglossus, hyoglossus, palatoglossus, and styloglossus), strap muscles, thyroid, or oesophagus T4b Tumour invades prevertebral space, encases carotid artery, or mediastinal structures Glottis T1 Tumour limited to vocal cord(s) (may involve anterior or posterior commissure) with normal mobility T1a Tumour limited to one vocal cord T1b Tumour involves both vocal cords T2 Tumour extends to supraglottis and/or subglottis, and/or with impaired vocal cord mobility T3 Tumour limited to larynx with vocal cord fixation and/or invades paraglottic space, and/or inner cortex of the thyroid cartilage T4a Tumour invades through the outer cortex of the thyroid cartilage, and/or invades tissues beyond the larynx, e.g., trachea, soft tissues of neck including deep/extrinsic muscle of tongue (genioglossus, hyoglossus, palatoglossus, and styloglossus), strap muscles, thyroid, oesophagus T4b Tumour invades prevertebral space, encases carotid artery, or mediastinal structures Subglottis T1 Tumour limited to subglottis T2 Tumour extends to vocal cord(s) with normal or impaired mobility T3 Tumour limited to larynx with vocal cord fixation T4a Tumour invades cricoid or thyroid cartilage and/or invades tissues beyond the larynx, e.g., trachea, soft tissues of neck including deep/

Larynx

33

extrinsic muscle of tongue (genioglossus, hyoglossus, pala toglossus, and styloglossus), strap muscles, thyroid, oesophagus T4b Tumour invades prevertebral space, encases carotid artery, or mediastinal structures

N – Regional Lymph Nodes Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension without extranodal extension N2 Metastasis described as: N2a Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension without extranodal extension N2b Metastasis in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension, without extranodal extension N2c Metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension, without extranodal extension N3a Metastasis in a lymph node more than 6 cm in greatest dimension without extranodal extension N3b Metastasis in a single or multiple lymph nodes with clinical ­extranodal extension* Notes * The presence of skin involvement or soft tissue invasion with deep fixation/ tethering to underlying muscle or adjacent structures or clinical signs of nerve involvement is classified as clinical extra nodal extension.

Midline nodes are considered ipsilateral nodes.

M – Distant Metastasis M0 No distant metastasis M1 Distant metastasis

pTNM Pathological Classification The pT categories correspond to the clinical T categories. For pM see page 8.

pN – Regional L ymph Nodes Histological examination of a selective neck dissection specimen will ­ordinarily include 10 or more lymph nodes. Histological examination of a radical or modified radical neck dissection specimen will ordinarily include 15 or more lymph nodes.

Head & Neck

N1

34

Head and Neck Tumours

pNX pN0 pN1

Regional lymph nodes cannot be assessed No regional lymph node metastasis Metastasis in a single ipsilateral lymph node, 3 cm or less in ­greatest dimension without extranodal extension pN2 Metastasis described as: pN2a Metastasis in a single ipsilateral lymph node, less than 3 cm in greatest dimension with extranodal extension or more than 3 cm but not more than 6 cm in greatest dimension without extranodal extension pN2b Metastasis in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension, without extranodal extension pN2c Metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension, without extranodal extension pN3a Metastasis in a lymph node more than 6 cm in greatest dimension without extranodal extension pN3b Metastasis in a lymph node more than 3 cm in greatest dimension with extranodal extension or multiple ipsilateral, or any contralateral or bilateral node(s) with extranodal extension

Stage Stage 0 Stage I Stage II Stage III Stage IVA Stage IVB Stage IVC

Tis T1 T2 T3 T1,T2,T3 T4a T1,T2,T3,T4a T4b Any T Any T

N0 N0 N0 N0 N1 N0, N1 N2 Any N N3 Any N

M0 M0 M0 M0 M0 M0 M0 M0 M0 M1

Larynx

35

Prognostic Factors Grid Prognostic factors

Tumour related

Host related

Environment related

Essential

T, N, M categories Extracapsular extension

Co‐morbidities Age >70 years Performance status

Able to provide standard treatment (resources) Treatment quality Resection margins

Additional

Regions/subsites involved Low neck nodes Tumour volume Vocal cord impairment Tracheostomy

Gender Laryngeal function

Nutrition Social/ environmental (e.g. anatomical station) Overall treatment time

New and promising

Tumour markers: TP53, VEGF, cyclin D1 amplifi cation, EGFR, Bcl‐2 Tumour HPV status Chemoresistance genes

Baseline quality of life

Optical imaging New sensitizers in photodynamic therapy

Source: UICC Manual of Clinical Oncology, Ninth Edition. Edited by Brian O’Sullivan, James D. Brierley, Anil K. D’Cruz, Martin F. Fey, Raphael Pollock, Jan B. Vermorken and Shao Hui Huang. © 2015 UICC. Published 2015 by John Wiley & Sons, Ltd.

Head & Neck

Prognostic factors for survival for laryngeal and hypopharyngeal carcinoma